Form 4: Acadia Pharmaceuticals EVP, CFO Mark Schneyer Reports Stock Transactions
SEC Form 4 Filing
Mark Schneyer, EVP and CFO of Acadia Pharmaceuticals, reports the vesting of restricted stock units and subsequent sale of shares to cover withholding taxes.
Summary
- On April 5, 2025, Mark Schneyer, the EVP and CFO of Acadia Pharmaceuticals, had 5,275 restricted stock units vest.
- These units convert into shares of Acadia Pharmaceuticals common stock.
- Following the vesting, Schneyer sold 2,708 shares on April 8, 2025, at a price of $14.82 per share.
- The sale was to cover withholding taxes related to the vesting of the restricted stock units.
- After these transactions, Schneyer directly owns 59,456 shares of Acadia Pharmaceuticals common stock and 5,276 restricted stock units.
Sentiment
Score: 7
Explanation: The document reflects standard executive compensation practices and stock transactions, which are neither particularly positive nor negative. The sentiment is neutral to slightly positive due to the executive's continued stock ownership.
Industry Context
This is a routine Form 4 filing, reflecting standard executive compensation practices involving stock options and restricted stock units. These filings are common and provide transparency into executive stock ownership.
Comparison to Industry Standards
- Executive compensation packages often include restricted stock units that vest over time.
- The sale of shares to cover tax obligations upon vesting is a standard practice.
- Comparing Schneyer's holdings and transactions to those of executives at similar-sized pharmaceutical companies (e.g., Neurocrine Biosciences, Biogen) would provide a benchmark for assessing the magnitude of his equity compensation.
Stakeholder Impact
- Shareholders are informed about executive stock transactions, promoting transparency.
- The transactions have a minimal direct impact on employees, customers, suppliers, or creditors.
Key Dates
| Date | Description |
|---|---|
| 04/05/2023 | Start date for the restricted stock units to vest in four equal annual installments |
| 04/05/2025 | Vesting of 5,275 restricted stock units. |
| 04/08/2025 | Sale of 2,708 shares at $14.82 per share. |
Keywords
Acadia Pharmaceuticals, Mark Schneyer, restricted stock units, Form 4, insider trading, stock sale, vesting, executive compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.